<?xml version="1.0" encoding="UTF-8"?>
<p>SOD activity in the stomach was significantly higher in the 100 mg/kg IFE- and Stillen-treated groups than in the control group (both 
 <italic>p</italic> &lt; 0.05, 
 <xref ref-type="fig" rid="molecules-25-05623-f004">Figure 4</xref>a). CAT activity was also higher in the IFE and Stillen groups than in the control group (
 <xref ref-type="fig" rid="molecules-25-05623-f004">Figure 4</xref>b). GSH levels were significantly higher in the 100 mg/kg IFE group than in the control group (
 <italic>p</italic> &lt; 0.01, 
 <xref ref-type="fig" rid="molecules-25-05623-f004">Figure 4</xref>c) but were not altered in the 300 mg/kg Stillen-treated group. MDA levels were significantly lower in the 100 and 300 mg/kg IFE- and Stillen-treated groups than in the control group (all 
 <italic>p</italic> &lt; 0.01, 
 <xref ref-type="fig" rid="molecules-25-05623-f004">Figure 4</xref>d).
</p>
